Back to article: Targeting immune-checkpoint inhibitor resistance mechanisms by MEK inhibitor and agonist anti-CD40 antibody combination therapy
FIGURE 2: Effect of cytostatic drugs on tumor and immune cells and during anti-tumor immunity. (A) Effect of MEKi on tumor cell viability, expression of pro-inflammatory genes and MHC-I/-II protein levels in presence of low doses IFNγ. Effect of MEKi and GEM on T cell expansion in in vivo OT-I T cell proliferation assays. (B) Anti-tumor efficacy and PD biomarker gene signatures of combinations therapies involving cytostatic agents GEM and MEKi and immunostimulatory antibodies targeting CD40 and PD-1.